Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Adv Ther (Weinh). 2020 Jun 9;3(9):2000044. doi: 10.1002/adtp.202000044

Figure 6: MBTA treatment induces immunological memory against CT26 cells.

Figure 6:

A) Tumor growth curves: Mice cured of CT26 colon carcinoma were re-challenged subcutaneously with 4.5×105 CT26 cells after 50 days from last treatment day. CT26 Naïve (black, n=4) and MBTA Pre-treated (pink, n=4) mice; B) Cumulative survival of re-challenged mice over time. Naïve vs MBTA pre-treated: **p = 0.0069 by Log-rank (Mantel-Cox) test; C) Representative bioluminescence imaging of intracranially re-challenged mice. Mice cured of CT26 colon carcinoma were also re-challenged intracranially with 1×104 CT26-Luc cells in the right frontal lobe (1 mm rostral of the bregma, 2 mm right of midline and 2 mm deep from the skull surface). MBTA Pre-treated (left, n=4) and Naïve (right, n=4); D) Cumulative survival of intracranially re-challenged mice over time; Naïve vs MBTA Pre-treated mice: *p = 0.0100 by Log-rank (Mantel-Cox) test.